Uncomplicated Peptic Ulcer with MCC DRG Reimbursement Guide

DRG 383 addresses inpatient admissions for uncomplicated peptic ulcer disease when a Major Complication or Comorbidity is present, affecting clinical care intensity. This Diagnosis-Related Group is important for inpatient reimbursement because the presence of a Major Complication or Comorbidity elevates the payment weight under the Medicare payment system.

DRG 383 Overview

DRG 383 covers hospital admissions for uncomplicated peptic ulcer disease with a Major Complication or Comorbidity. This Diagnosis-Related Group captures cases where the primary peptic ulcer condition requires inpatient management and the presence of a Major Complication or Comorbidity increases resource use. It matters for Medicare payment because the assigned Diagnosis-Related Group level directly influences the prospective payment rate that hospitals receive for the episode. Accurate clinical coding and documentation of the Major Complication or Comorbidity affect reimbursement and case classification.

Acute hemostatic and endoscopic intervention studies: randomized or prospective cohort studies evaluating timing, technique, or adjuncts to endoscopic therapy for bleeding peptic ulcers in hospitalized patients with major complications (MCC) such as significant hemorrhage, shock, or hemodynamic instability. These trials enroll patients admitted emergently with active ulcer bleeding to compare immediate endoscopic modalities, blood product strategies, or procedural adjuncts to achieve durable hemostasis. Findings are directly relevant to inpatient providers and payers because they affect length of stay, transfusion needs, intensive care utilization, and immediate resource intensity for DRG 383 admissions.
Comparative effectiveness studies of ulcer etiology and comorbidity management: observational or pragmatic trials comparing strategies to manage underlying contributors (for example, H. pylori testing and eradication pathways, NSAID cessation with alternative analgesia, or coordination of anticoagulation reversal and resumption) in patients with complicated ulcers and significant comorbid conditions. These studies focus on older patients or those with cardiovascular disease, chronic kidney disease, or chronic anticoagulation whose comorbidities drive complication severity and readmission risk. Results inform bundled care pathways and payer decisions by identifying approaches that reduce complications, readmissions, and downstream costs for the DRG cohort.
Post-discharge outcomes and transitional care trials: randomized or cohort studies of discharge planning, gastroenterology follow-up timing, medication adherence programs, and outpatient surveillance to prevent rebleeding or readmission among patients recently discharged after an uncomplicated peptic ulcer admission with MCC. These trials enroll patients at discharge and measure 30- and 90-day readmission rates, rebleeding events, and outpatient resource use, often stratified by social risk factors or comorbidity burden. Evidence from these studies helps hospitals and payers design care transition interventions that reduce costly readmissions and optimize post-acute resource allocation for this DRG population.

Acute hemostatic and endoscopic intervention studies: randomized or prospective cohort studies evaluating timing, technique, or adjuncts to endoscopic therapy for bleeding peptic ulcers in hospitalized patients with major complications (MCC) such as significant hemorrhage, shock, or hemodynamic instability. These trials enroll patients admitted emergently with active ulcer bleeding to compare immediate endoscopic modalities, blood product strategies, or procedural adjuncts to achieve durable hemostasis. Findings are directly relevant to inpatient providers and payers because they affect length of stay, transfusion needs, intensive care utilization, and immediate resource intensity for DRG 383 admissions.
Comparative effectiveness studies of ulcer etiology and comorbidity management: observational or pragmatic trials comparing strategies to manage underlying contributors (for example, H. pylori testing and eradication pathways, NSAID cessation with alternative analgesia, or coordination of anticoagulation reversal and resumption) in patients with complicated ulcers and significant comorbid conditions. These studies focus on older patients or those with cardiovascular disease, chronic kidney disease, or chronic anticoagulation whose comorbidities drive complication severity and readmission risk. Results inform bundled care pathways and payer decisions by identifying approaches that reduce complications, readmissions, and downstream costs for the DRG cohort.
Post-discharge outcomes and transitional care trials: randomized or cohort studies of discharge planning, gastroenterology follow-up timing, medication adherence programs, and outpatient surveillance to prevent rebleeding or readmission among patients recently discharged after an uncomplicated peptic ulcer admission with MCC. These trials enroll patients at discharge and measure 30- and 90-day readmission rates, rebleeding events, and outpatient resource use, often stratified by social risk factors or comorbidity burden. Evidence from these studies helps hospitals and payers design care transition interventions that reduce costly readmissions and optimize post-acute resource allocation for this DRG population.

OpenPayer

Summary & Overview

Uncomplicated Peptic Ulcer with Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 383 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes